The great debate part II: should managed care rely on cost sharing to manage big-ticket biologics?
Zitter
Mark
M
The Zitter Group, Millburn, NJ 07041, USA. mzitter@zitter.com
D001688:Biological Products / Q000191:economics*; D017047:Cost Sharing / Q000191:economics*; D003362:Cost-Benefit Analysis / Q000379:methods; D016527:Drug Costs / Q000639:trends; D005544:Forecasting; D017408:Guidelines as Topic; D006801:Humans; D008329:Managed Care Programs / Q000191:economics*; D014481:United States
D001688:Biological Products